Expand Your Cell-based Assays With an Unlimited, Biologically Relevant Resource
Yalin Firinci, M.B.A., is adept at developing next generation biological models that incorporate primary cells. Join this webinar to hear this ATCC expert cover the following key points:
- Differentiated iPSCs lend the ability to run large toxicity studies and drug screens on highly biologically relevant cells.
- ATCC iPSCs were used as the source for three types of differentiated cells: CD34+ progenitors, mesenchymal stem cells (MSCs), and monocytes.
- ATCC R&D scientists have generated in-depth data showing the iPSC-derived cells can be incorporated into immunoassays and further differentiated into cell types such as osteocytes, chondrocytes, and adipocytes.